Posts Tagged: "Andrei Iancu"

Iancu to Receive 2022 Paul Michel Award at IPWatchdog LIVE in Texas

In consultation with Chief Judge Paul Michel, IPWatchdog is pleased to announce that Andrei Iancu, former Under Secretary of Commerce for Intellectual Property and Director of the USPTO, and current partner at Irell & Manella, has been selected as the 2022 recipient of The Paul Michel Award. He will be presented with the award on Sunday evening, September 11, 2022, at IPWatchdog LIVE 2022. The Paul Michel Award, created with the blessing of Chief Judge Paul Michel (CAFC, ret.), is awarded annually to someone within the IP community who has selflessly served the best interests of the industry and its members as a respected leader, mentor, and advocate on behalf of fairness and for the best interests of the intellectual property system.

PTAB Masters™ 2022, Day Three: Iancu Slams Repeat Proceedings, Panelists Opine on Breyer Retirement

The third day of IPWatchdog’s PTAB Masters™ 2022 featured more from former U.S. Patent and Trademark Office (USPTO) Director Andrei Iancu, as well as panels covering topics such as avoiding obviousness mistakes, appellate strategies from the Patent Trial and Appeal Board (PTAB) and other intricacies of PTAB practice from the experts. Panelists this afternoon also weighed in on today’s announcement that Justice Stephen Breyer will retire from the Supreme Court, opening the door for Biden to appoint a replacement.

On Day Two of PTAB Masters™ 2022, Panelists Dig into Data Showing Fintiv Denials May Be Dead for Texas Cases

The first panel of Tuesday’s PTAB Masters™ 2022, titled “Discretionary Denials: Has the WDTX Been Neutered?”, presented data that reveals the U.S. Patent and Trademark Office’s (USPTO’s) Patent Trial and Appeal Board (PTAB) seemingly stopped citing Fintiv as a reason to discretionarily deny inter partes review (IPR) proceedings for cases with parallel litigation in the Western or Eastern Districts of Texas (WD of TX/ ED of TX) during the last four months of 2021. While the PTAB issued a larger number of institution decisions overall in those months compared with previous months, and a larger number of cases citing Fintiv, there was also a relatively low number of cases across all jurisdictions in which discretion to deny was applied based on the Fintiv analysis.

Day One of PTAB Masters™ 2022: Tillis and Iancu Chime in on PTAB and Patent System Problems

The first day of IPWatchdog’s PTAB Masters™ 2022 program featured a welcome from Senator Thom Tillis (R-NC), Ranking Member of the Senate Judiciary Committee’s Subcommittee on Intellectual Property, who told attendees that Congress should consider codifying some of the reforms made by former U.S. Patent and Trademark Office (USPTO) Director Andrei Iancu in order to better avoid “gamesmanship” at the Patent Trial and Appeal Board. Tillis specifically called out entities like OpenSky Industries, who last December petitioned the PTAB to institute an IPR proceeding challenging claims from one of two patents involved in VLSI Technologies’ $2.175 billion jury verdict for patent infringement against Intel, which was handed down in March 2021 in the Western District of Texas.

Iancu and Kappos: TRIPS IP Waiver Proposal Will Kill More People Than It Saves

A webinar hosted on Tuesday, January 12, by The Federalist Society’s Regulatory Transparency Project featured former U.S. Patent and Trademark Office (USPTO) Directors Andrei Iancu and David Kappos, as well as Duke University Professor of Law and former USPTO Administrator of the Office of External Affairs Arti Rai, discussing the proposal to the World Trade Organization (WTO) to waive IP rights under the Trade-Related aspects of Intellectual Property Rights (TRIPS) Agreement for certain COVID-19 technologies. While all three panelists agreed that the IP waiver discussion has become a distraction that will not solve the fundamental problems, Iancu and Kappos were especially passionate that the precedent set by the U.S. government’s decision to back the proposal could do very real harm, rather than good.